Max S. Topp
YOU?
Author Swipe
View article: 103 | A PHASE 1 STUDY OF KITE‐363 ANTI‐CD19/CD20 CHIMERIC ANTIGEN RECEPTOR (CAR) T‐CELL THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) B‐CELL LYMPHOMA
103 | A PHASE 1 STUDY OF KITE‐363 ANTI‐CD19/CD20 CHIMERIC ANTIGEN RECEPTOR (CAR) T‐CELL THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) B‐CELL LYMPHOMA Open
View article: 280 | GLOFITAMAB COMBINED WITH R‐CHOP OR POLA‐R‐CHP IN PATIENTS WITH PREVIOUSLY UNTREATED DIFFUSE LARGE B‐CELL LYMPHOMA: FINAL RESULTS FROM THE NP40126 STUDY
280 | GLOFITAMAB COMBINED WITH R‐CHOP OR POLA‐R‐CHP IN PATIENTS WITH PREVIOUSLY UNTREATED DIFFUSE LARGE B‐CELL LYMPHOMA: FINAL RESULTS FROM THE NP40126 STUDY Open
View article: Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3
Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3 Open
View article: Odronextamab monotherapy in R/R DLBCL after progression with CAR T-cell therapy: primary analysis of the ELM-1 study
Odronextamab monotherapy in R/R DLBCL after progression with CAR T-cell therapy: primary analysis of the ELM-1 study Open
Patients with relapsed/refractory diffuse large B-cell lymphoma progressing after chimeric antigen receptor T-cell (CAR-T) therapy have dismal outcomes. The prespecified post–CAR-T expansion cohort of the ELM-1 study investigated the effic…
View article: EASIX-guided risk stratification for complications and outcome after CAR T-cell therapy with ide-cel in relapsed/refractory multiple myeloma
EASIX-guided risk stratification for complications and outcome after CAR T-cell therapy with ide-cel in relapsed/refractory multiple myeloma Open
Background Chimeric antigen receptor (CAR) T-cell therapy has demonstrated significant benefits in the treatment of relapsed/refractory multiple myeloma (RRMM). However, these outcomes can be compromised by severe complications, including …
View article: Changes in T‐cell subsets, preexisting cytopenias and hyperferritinaemia correlate with cytopenias after <scp>BCMA</scp> targeted <scp>CAR</scp> T‐cell therapy in relapsed/refractory multiple myeloma: Results from a prospective comprehensive biomarker study
Changes in T‐cell subsets, preexisting cytopenias and hyperferritinaemia correlate with cytopenias after <span>BCMA</span> targeted <span>CAR</span> T‐cell therapy in relapsed/refractory multiple myeloma: Results from a prospective comprehensive biomarker study Open
Summary Biomarkers for cytopenias following CAR T‐cell treatment in relapsed/refractory (RR) multiple myeloma (MM) are not completely defined. We prospectively analysed 275 sequential peripheral blood (PB) samples from 58 RRMM patients tre…
View article: Measurable residual disease quantification in adult patients with KMT2A-rearranged acute lymphoblastic leukemia
Measurable residual disease quantification in adult patients with KMT2A-rearranged acute lymphoblastic leukemia Open
In adult ALL, 5-10% of patients show KMT2A translocations (KMT2A rearrangements) with only a few secondary alterations, implicating it as a leukemia-initiating factor [1,2].Approximately 95% of all fusions in adult ALL are KMT2A::AFF1 or K…
View article: Molecular assessment of intratumoral immune cell subsets and potential mechanisms of resistance to odronextamab, a CD20×CD3 bispecific antibody, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma
Molecular assessment of intratumoral immune cell subsets and potential mechanisms of resistance to odronextamab, a CD20×CD3 bispecific antibody, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma Open
Background Patients with relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL) have a significant need for effective treatment options. Odronextamab is an Fc-silenced, human, CD20×CD3 bispecific antibody that targets CD20-expressing …
View article: Approaches for bridging therapy prior to chimeric antigen receptor T cells for relapsed/refractory acute lymphoblastic B-lineage leukaemia in children and young adults
Approaches for bridging therapy prior to chimeric antigen receptor T cells for relapsed/refractory acute lymphoblastic B-lineage leukaemia in children and young adults Open
The ongoing development of immunotherapies, including chimeric antigen receptor (CAR) T cells, has revolutionized cancer treatment. In paediatric relapsed/refractory B-lineage acute leukaemia antiCD19-CARs induced impressive initial respon…
View article: CXCR4-targeted Theranostics in Hematooncology: Opportunities and Challenges
CXCR4-targeted Theranostics in Hematooncology: Opportunities and Challenges Open
C-X-C motif chemokine receptor 4 (CXCR4) is overexpressed in a multitude of cancers, including neoplasms of hematopoietic origin. This feature can be leveraged by a theranostic approach, which provides a read-out of the actual CXCR4 expres…
View article: Impact of debulking therapy on the clinical outcomes of axicabtagene ciloleucel in the treatment of relapsed or refractory large B-cell lymphoma
Impact of debulking therapy on the clinical outcomes of axicabtagene ciloleucel in the treatment of relapsed or refractory large B-cell lymphoma Open
Axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor T-cell therapy, was approved for relapsed/refractory (R/R) large B-cell lymphoma (LBCL) based on the results from pivotal Cohorts 1+2 of ZUMA-1 (NCT023482…
View article: Sequential antigen loss and branching evolution in lymphoma after CD19- and CD20-targeted T-cell–redirecting therapy
Sequential antigen loss and branching evolution in lymphoma after CD19- and CD20-targeted T-cell–redirecting therapy Open
CD19 chimeric antigen receptor (CAR) T cells and CD20 targeting T-cell–engaging bispecific antibodies (bispecs) have been approved in B-cell non-Hodgkin lymphoma lately, heralding a new clinical setting in which patients are treated with b…
View article: Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphoma
Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphoma Open
View article: Chemokine Receptor PET/CT Provides Relevant Staging and Management Changes in Marginal Zone Lymphoma
Chemokine Receptor PET/CT Provides Relevant Staging and Management Changes in Marginal Zone Lymphoma Open
Because of gastral and extranodal manifestations, guideline-compatible diagnostic work-up of marginal zone lymphoma is challenging. We aimed to determine the diagnostic performance of C-X-C motif chemokine receptor 4 (CXCR4)-directed PET/C…
View article: The sensitivity of rapid tests for SARS-CoV-2 antigen
The sensitivity of rapid tests for SARS-CoV-2 antigen Open
View article: Outcomes of axicabtagene ciloleucel in PMBCL compare favorably with those in DLBCL: a GLA/DRST registry study
Outcomes of axicabtagene ciloleucel in PMBCL compare favorably with those in DLBCL: a GLA/DRST registry study Open
View article: P367: LONG-TERM OUTCOMES OF ADULTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA TREATED WITH BREXUCABTAGENE AUTOLEUCEL IN ZUMA-3 BY AGE, PRIOR THERAPIES, AND SUBSEQUENT TRANSPLANT
P367: LONG-TERM OUTCOMES OF ADULTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA TREATED WITH BREXUCABTAGENE AUTOLEUCEL IN ZUMA-3 BY AGE, PRIOR THERAPIES, AND SUBSEQUENT TRANSPLANT Open
Background: Brexucabtagene autoleucel (brexu-cel) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy approved in the US for adults with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) and in th…
View article: Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3
Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3 Open
Background Brexucabtagene autoleucel (brexu-cel) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy approved in the USA for adults with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) and in …
View article: Enolase 1 of <i>Candida albicans</i> binds human CD4<sup>+</sup> T cells and modulates naïve and memory responses
Enolase 1 of <i>Candida albicans</i> binds human CD4<sup>+</sup> T cells and modulates naïve and memory responses Open
To obtain a better understanding of the biology behind life‐threatening fungal infections caused by Candida albicans , we recently conducted an in silico screening for fungal and host protein interaction partners. We report here that the e…
View article: Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations
Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations Open
Hematological toxicity is the most common adverse event after chimeric antigen receptor (CAR) T-cell therapy. Cytopenias can be profound and long-lasting and can predispose for severe infectious complications. In a recent worldwide survey,…
View article: Lymphoma-Sink Effect in Marginal Zone Lymphoma Based on CXCR4-Targeted Molecular Imaging
Lymphoma-Sink Effect in Marginal Zone Lymphoma Based on CXCR4-Targeted Molecular Imaging Open
View article: Glofitamab plus immunochemotherapy demonstrates durable efficacy with manageable safety in relapsed/refractory non‐Hodgkin lymphoma (R/R NHL): update of a Phase Ib study
Glofitamab plus immunochemotherapy demonstrates durable efficacy with manageable safety in relapsed/refractory non‐Hodgkin lymphoma (R/R NHL): update of a Phase Ib study Open
Introduction: Glofitamab (Glofit) is a novel T-cell engaging bispecific antibody. Its 2:1 molecular configuration allows bivalent binding to CD20 on B cells and monovalent binding to CD3 on T cells, enabling combination with anti-CD20 anti…
View article: Axicabtagene ciloleucel (Axicel) for relapsed/refractory primary mediastinal B‐cell lymphoma (r/r PMBCL) compared to DLBCL‐NOS: A GLA/DRST registry study.
Axicabtagene ciloleucel (Axicel) for relapsed/refractory primary mediastinal B‐cell lymphoma (r/r PMBCL) compared to DLBCL‐NOS: A GLA/DRST registry study. Open
Introduction: Axicel is approved for treatment of r/r PMBCL beyond the 2nd treatment line (>2L). However, real-world data on axicel safety and efficacy in this orphan entity is limited. Here, we present a comparison of standard-of-care axi…
View article: 3‐Year outcomes of adults with relapsed or refractory B‐cell acute lymphoblastic leukemia treated with brexu‐cel in ZUMA‐3 by age, prior therapies, and subsequent transplant
3‐Year outcomes of adults with relapsed or refractory B‐cell acute lymphoblastic leukemia treated with brexu‐cel in ZUMA‐3 by age, prior therapies, and subsequent transplant Open
Background: Brexucabtagene autoleucel (brexu-cel) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy approved in the US for adults with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) and in th…
View article: Sequential Antigen-loss and Branching Evolution in Lymphoma after Anti-CD19 and Anti-CD20 Targeted T Cell Redirecting Immunotherapy
Sequential Antigen-loss and Branching Evolution in Lymphoma after Anti-CD19 and Anti-CD20 Targeted T Cell Redirecting Immunotherapy Open
CD19 CAR T cells and CD20 targeting T cell engaging bispecific antibodies have been approved in B-cell Non-Hodgkin lymphoma lately, heralding a new clinical setting where patients are treated with both approaches, sequentially. The aim of …
View article: Supplementary Table 1 from An Open-Label, Multicenter, Phase I/II Study of JNJ-40346527, a CSF-1R Inhibitor, in Patients with Relapsed or Refractory Hodgkin Lymphoma
Supplementary Table 1 from An Open-Label, Multicenter, Phase I/II Study of JNJ-40346527, a CSF-1R Inhibitor, in Patients with Relapsed or Refractory Hodgkin Lymphoma Open
Supplementary Table 1: Extent of Exposure
View article: Data from An Open-Label, Multicenter, Phase I/II Study of JNJ-40346527, a CSF-1R Inhibitor, in Patients with Relapsed or Refractory Hodgkin Lymphoma
Data from An Open-Label, Multicenter, Phase I/II Study of JNJ-40346527, a CSF-1R Inhibitor, in Patients with Relapsed or Refractory Hodgkin Lymphoma Open
Purpose: This phase I/II study investigated JNJ-40346527, a selective inhibitor of the colony-stimulating factor-1 receptor (CSF-1R) tyrosine kinase as treatment for relapsed or refractory classical Hodgkin lymphoma (cHL).Experim…
View article: Data from An Open-Label, Multicenter, Phase I/II Study of JNJ-40346527, a CSF-1R Inhibitor, in Patients with Relapsed or Refractory Hodgkin Lymphoma
Data from An Open-Label, Multicenter, Phase I/II Study of JNJ-40346527, a CSF-1R Inhibitor, in Patients with Relapsed or Refractory Hodgkin Lymphoma Open
Purpose: This phase I/II study investigated JNJ-40346527, a selective inhibitor of the colony-stimulating factor-1 receptor (CSF-1R) tyrosine kinase as treatment for relapsed or refractory classical Hodgkin lymphoma (cHL).Experim…
View article: Supplementary Table 1 from An Open-Label, Multicenter, Phase I/II Study of JNJ-40346527, a CSF-1R Inhibitor, in Patients with Relapsed or Refractory Hodgkin Lymphoma
Supplementary Table 1 from An Open-Label, Multicenter, Phase I/II Study of JNJ-40346527, a CSF-1R Inhibitor, in Patients with Relapsed or Refractory Hodgkin Lymphoma Open
Supplementary Table 1: Extent of Exposure
View article: General condition and comorbidity of long-term survivors of adult acute lymphoblastic leukemia
General condition and comorbidity of long-term survivors of adult acute lymphoblastic leukemia Open
Cure rates in adult acute lymphoblastic leukemia (ALL) improved using pediatric-based chemotherapy and stem cell transplantation (SCT). However, limited data on the health condition of cured adults are available whereas pediatric data cann…